

"In Memory of Sante Tura"

Program

HEMATOLOGY SUMMIT

May 13-15, 2025

Bologna, Royal Hotel Carlton

President: Pier Luigi Zinzani



Auspices

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

GITMO - Gruppo Italiano Trapianto Midollo Osseo

IRCCS Azienda Ospedaliero Universitaria di Bologna
Policlinico di Sant'Orsola

Faculty

Jeremy S.	Abramson	Boston, USA
Sergio	Amadori	Roma, Italy
Stephen M.	Ansell	Rochester, USA
Emmanuel	Bachy	Lyon, France
Alessandra	Brescianini	Milano, Italy
Antonio	Cuneo	Ferrara, Italy
Matthew S.	Daids	Boston, USA
Enrico	Derenzini	Milano, Italy
Alice	Di Rocco	Roma, Italy
Hermann	Einsele	Würzburg, Germany
Lorenzo	Falchi	New York, USA
Simone	Ferrero	Torino, Italy
Gianluca	Gaidano	Novara, Italy
Saar	Gill	Philadelphia, USA
Florian	Heidel	Hannover, Germany
Alex F.	Herrera	Duarte, USA
Georg	Hess	Mainz, Germany
Steven M.	Horwitz	New York, USA
Martin	Hutchings	Copenhagen, Denmark
Swaminathan P.	Iyer	Houston, USA
Caron A.	Jacobson	Boston, USA
Luca	Laurenti	Roma, Italy
Steven	Le Gouill	Paris, France
Georg	Lenz	Münster, Germany
Mark J.	Levis	Baltimore, USA
Franco	Locatelli	Roma, Italy
Izidore	Lossos	Miami, USA
Stefano	Luminari	Reggio Emilia, Italy
Silvia	Mangiacavalli	Pavia, Italy
Thomas G.	Martin	San Francisco, USA
John	Mascarenhas	New York, USA
Ruben	Mesa	Charlotte, USA
Giorgio	Minotti	Roma, Italy
Emili	Montserrat	Barcelona, Spain

General information

Philippe Frank	Moreau	Nantes, France
Craig H. Alison	Morschhauser	Lille, France
Lori Gerardo	Moskowitz	Miami, USA
Sattva S. Tycell	Moskowitz	New York, USA
Stefano A. Antonio	Muffly	Stanford, USA
Katy Philippe	Musuraca	Meldola - FC, Italy
Armando Bart	Neelapu	Houston, USA
Mikkael John	Phillips	Duarte, USA
Paolo Paolo	Pileri	Bologna - Milano, Italy
Marion Alessandra	Pinto	Napoli, Italy
Catherine Livio	Rezvani	Houston, USA
Steven Umberto	Rousselot	Paris, France
Ajay Jason R.	Santoro	Rozzano - MI, Italy
Jennifer Amer	Scott	Seattle, USA
Pier Luigi	Sekeres	Miami, USA
	Seymour	Melbourne, Australia
	Sportoletti	Perugia, Italy
	Strati	Houston, USA
	Subklewe	München, Germany
	Tedeschi	Milano, Italy
	Thieblemont	Paris, France
	Trentin	Padova, Italy
	Treon	Boston, USA
	Vitolo	Candiolo - TO, Italy
	Vora	London, United Kingdom
	Westin	Houston, USA
	Woyach	Columbus, USA
	Zeidan	New Haven, USA
	Zinzani	Bologna, Italy

MEETING VENUE

Royal Hotel Carlton
Via Montebello, 8 - 40121 Bologna, Italy
www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION

The Organizing Secretariat will offer a **travel grant** to the first 50 registered attendees to cover hotel and travel expenses.

Registration is free and available at www.ercongressi.it - section "I nostri congressi/2025".

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions.

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

An application for Italian CME credits has been made by Studio ER Congressi srl (ID 828) for physicians (discipline: hematology, oncology, pathological anatomy, clinical pathology) and biologists.

The educational objective is "guidelines-protocols-procedures".

CME accreditation has been divided as follows:

- 1st part ID 436141: Tuesday 13, 2025 morning - N. 1,2 CME credits
- 2nd part ID 436142: Tuesday 13, 2025 afternoon - N. 0,6 CME credits
- 3rd part ID 436143: Wednesday 14, 2025 morning - N. 1,2 CME credits
- 4th part ID 436144: Wednesday 14, 2025 afternoon - N. 0,6 CME credits
- 5th part ID 436147: Thursday 15, 2025 - N. 0,9 CME credits

To obtain CME credits for each accreditation it is necessary to:

- Attend at least 90% of the scientific works. Attendance in the hall will be tracked by electronic badge.
- Complete and return the CME forms to the reception desk.

Please note that the Sponsored Lectures and the Pills of Science do not belong to the CME accreditation.

09.00 am **Welcome and introduction** - P.L. Zinzani
Sante Tura - Master of science and life: an unforgettable and unique man

- Remembering Sante - E. Montserrat
- The scientist - S. Amadori
- The man - S.A. Pileri

09.45 am **SESSION 1. HOT NEWS: Hodgkin lymphoma**

Chairman: C.H. Moskowitz

- Frontline therapy - A.F. Herrera
- Relapsed/refractory therapy - A. Moskowitz
- Newer agents - C.H. Moskowitz
- Round table: C.H. Moskowitz, A.F. Herrera, A. Moskowitz

11.00 am **SESSION 2. HOT NEWS: Chronic lymphocytic leukemia**

Chairman: J. Seymour

- Frontline therapy - J. Seymour
- Relapsed/refractory therapy - M.S. Davids
- Newer agents - J. Wojach
- Round table: J. Seymour, M.S. Davids, J. Wojach

12.15 pm **SESSION 3. HOT NEWS: Ph1-neg myeloproliferative neoplasms**

Chairman: J. Mascarenhas

- New targets for therapy - R. Mesa
- Novel therapies - J. Mascarenhas
- Future therapies - F. Heidel
- Round table: J. Mascarenhas, R. Mesa, F. Heidel

01.30 pm *Lunch*

02.30 pm **SPONSORED LECTURE 1**

03.00 pm **SPONSORED LECTURE 2**

details on page 12

03.30 pm **SESSION 4. HOT NEWS: Aggressive non-Hodgkin lymphoma**

Chairman: S.M. Ansell

- Incorporation of novel agents into frontline therapy
S.M. Ansell
- The last of a new concept in frontline: SMART STOP
J.R. Westin
- Bispecifics vs CAR-T today and tomorrow
M. Hutchings vs J.S. Abramson
- Round table: S.M. Ansell, J.R. Westin, M. Hutchings, J.S. Abramson

05.00 pm **SESSION 5. HOT NEWS: Myelodysplastic syndromes**

Chairman: M. Sekeres

- Treatment of lower-risk - A. Zeidan
- Treatment of higher-risk - M. Sekeres
- Transplantation - B. Scott
- Round table: M. Sekeres, A. Zeidan, B. Scott

06.15 pm **SPONSORED LECTURE 3**

06.45 pm **SPONSORED LECTURE 4**

details on page 12

08.30 am **SESSION 6. HOT NEWS: CAR-T**

Chairman: S.S. Neelapu

- Allo CAR-T - S.S. Neelapu
- NK CAR-T - K. Rezvani
- Novel CAR-T and CAR-T combinations
J.S. Abramson (NHL), H. Einsele (MM)
- Round table: S.S. Neelapu, K. Rezvani, J.S. Abramson, H. Einsele

10.00 am **SESSION 7. HOT NEWS: Acute myeloid leukemias**

Chairman: M.J. Levis

- Targeted therapy - M.J. Levis
- Bispecifics - M. Subklewe
- CAR-T cells - S. Gill
- Round table: M.J. Levis, M. Subklewe, S. Gill

11.15 am **SESSION 8. HOT NEWS: Indolent non-Hodgkin lymphoma**

Chairman: F. Morschhauser

- We are close to “chemo-free” therapy in frontline
F. Morschhauser
- Bispecifics vs CAR-T today and tomorrow
L. Falchi vs C.A. Jacobson
- Newer agents - P. Strati
- Round table: F. Morschhauser, L. Falchi, C.A. Jacobson, P. Strati

12.45 pm *Lunch*

01.45 pm **SPONSORED LECTURE 5**

02.15 pm **SPONSORED LECTURE 6**

details on page 13

02.45 pm **SESSION 9. HOT NEWS: Marginal zone lymphoma & Waldenström macroglobulinemia**

Chairman: C. Thieblemont

- The world of MALT-lymphoma - I. Lossos
- BTKi and new agents in relapsed/refractory MZL patients - C. Thieblemont
- Update on Waldenström macroglobulinemia - S. Treon
- Round table: C. Thieblemont, I. Lossos, S. Treon

04.00 pm **SESSION 10. HOT NEWS: Peripheral T-cell lymphoma**

Chairman: S.M. Horwitz

- Tailoring therapy in frontline - S.M. Horwitz
- Is there a role for autotransplant consolidation in frontline? - E. Bachy
- New targeted therapies in relapse/refractory patients
S. Iyer
- Round table: S.M. Horwitz, E. Bachy, S. Iyer

05.15 pm **SPONSORED LECTURE 7**

05.45 pm **SPONSORED LECTURE 8**

06.15 pm **SPONSORED LECTURE 9**

details on page 13

08.30 am **PILLS OF SCIENCE**

Chairman: P.L. Zinzani

- **SPONSORED PILL 1**
- **SPONSORED PILL 2**
- **SPONSORED PILL 3**
- **SPONSORED PILL 4**
- **SPONSORED PILL 5**
- **SPONSORED PILL 6**

details on page 14

10.00 am **SESSION 11. HOT NEWS: Mantle cell lymphoma**

Chairman: G. Hess

- Optimal treatment for younger patients - G. Hess
- Treatment algorithm for older patients - S. Le Gouill
- Novel agents - T. Phillips
- Round table: G. Hess, S. Le Gouill, T. Phillips

11.15 am **SESSION 12. HOT NEWS: Acute lymphoblastic leukemia**

Chairman: A. Vora

- Management of younger patients - A. Vora
- Management of older patients - P. Rousselot
- Novel agents - L. Muffly
- Round table: A. Vora, P. Rousselot, L. Muffly

12.30 pm **SESSION 13. HOT NEWS: Multiple myeloma**

Chairman: P. Moreau

- The therapeutic algorithm is like a “sudoku”- P. Moreau
- Bispecific vs CAR-T - T.G. Martin vs H. Einsele
- Indefinite treatment for frail patients? - H. Einsele
- Round table: P. Moreau, T.G. Martin, H. Einsele

01.15 pm *Arrivederci!*

- 02.30 pm **SWEDISH ORPHAN BIOVITRUM S.R.L. (SOBI) SPONSORED LECTURE 1**
Loncastuximab tesirine in DLBCL R/R: treatment sequencing opportunities in a complex algorithm - E. Derenzini, G. Lenz
- 03.00 pm **BEONE MEDICINES ITALY S.R.L. SPONSORED LECTURE 2**
Setting new standard in CLL: Zanubrutinib as a balance between efficacy and safety
- Potency and selectivity of Zanubrutinib in B-cell malignancies - A. Tedeschi
 - Clinical data of Zanubrutinib in CLL: balance between efficacy and safety - L. Laurenti
- 06.15 pm **JANSSEN CILAG S.P.A. (GRUPPO JOHNSON AND JOHNSON) SPONSORED LECTURE 3**
Revolutionizing CLL Therapy: the impact of fixed-duration therapy and innovative pharmacological synergies
- Evolution of CLL treatment: the effectiveness of fixed-duration therapy - P. Sportoletti
 - The innovative synergy: pharmacological basis in therapy selection - G. Minotti
- 06.45 pm **ROCHE S.P.A SPONSORED LECTURE 4**
Frontline DLBCL: unmet clinical needs and treatment matrix - A. Pinto

- 01.45 pm **ASTRAZENECA S.P.A. SPONSORED LECTURE 5**
How fitness influences treatment in CLL? - A. Cuneo
- 02.15 pm **GILEAD SCIENCES S.R.L. SPONSORED LECTURE 6**
Chairman: A. Santoro
Axi-cel and brexu-cel: the real-world effectiveness - S. Luminari
- 05.15 pm **NOVARTIS FARMA S.P.A. SPONSORED LECTURE 7**
Tisagenlecleucel in follicular lymphoma: from clinical trials to real-world evidence - C. Thieblemont
- 05.45 pm **ABBVIE S.R.L. SPONSORED LECTURE 8**
Venetoclax and epcoritamab: elevate the standard of care in CLL and DLBCL - G. Gaidano, L. Trentin
- 06.15 pm **BRISTOL MYERS SQUIBB S.R.L SPONSORED LECTURE 9**
Role of liso-cel in the therapeutic algorithm for patients with R/R DLBCL - A. Di Rocco

- 08.30 am **INCYTE BIOSCIENCES ITALY S.R.L. SPONSORED PILL 1**
What real-world data tell us about Tafasitamab in r/r DLBCL - G. Musuraca
- 08.45 am **MENARINI STEMLINE ITALIA S.R.L. SPONSORED PILL 2**
Selinexor: exploring a new mechanism of action for the treatment of multiple myeloma - S. Mangiacavalli
- 09.00 am **AMGEN S.R.L. SPONSORED PILL 3**
Bi-specific T cell engager: a revolution in the treatment of oncohematological diseases - A. Brescianini
- 09.15 am **MSD SPONSORED PILL 4**
New treatments for classical Hodgkin lymphoma. Breakthrough therapies in frontline cHL and what's next - U. Vitolo
- 09.30 am **ELI LILLY ITALIA S.P.A. SPONSORED PILL 5**
Relapsed/refractory mantle cell lymphoma: the role of Pirtobrutinib in the therapeutic algorithm - S. Ferrero
- 09.45 am **VERTEX PHARMACEUTICALS (ITALY) S.R.L. SPONSORED PILL 6**
The gene therapy's perspectives in hereditary hematological diseases - F. Locatelli

Acknowledgements

With the unrestricted educational grant of

abbvie

AstraZeneca 

 BeOne

 Bristol Myers Squibb®

 GILEAD |  Kite

Johnson & Johnson

 NOVARTIS

 Roche

 sobi
rare strength

 GSK

 Takeda

AMGEN

Lilly
A MEDICINE COMPANY

 Incyte |  SOLVE
ON.

 MENARINI Stemline

 MSD

 VERTEX

 NURIX

 SERB
Pharmaceuticals

SCIENTIFIC SECRETARIAT

Pier Luigi Zinzani

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli"

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Università di Bologna - Via Massarenti, 9 - 40138 Bologna, Italy

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559

E-mail: ercongressi@ercongressi.it

www.ercongressi.it